Serum Levels of miR-143 Predict Survival in Critically Ill Patients

Christoph Roderburg, 1,2 Alexander Koch, 1 Fabian Benz, 1,2 Mihael Vucur, 1 Martina Spehlmann, 1 Sven H. Loosen, 1 Mark Luedde, 3 Sebastian Rehse, 4 Georg Lurje, 5 Christian Trautwein, 1 Frank Tacke, 1,2 and Tom Luedde 1,6

1 Department of Medicine III, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany
2 Department of Gastroenterology/Hepatology, Charité University Medical Center Berlin, Campus Virchow Klinikum and Charité Mitte, Augustenburger Platz 1, 13353 Berlin, Germany
3 Department of Internal Medicine III, University of Kiel, Schittenhelmstrasse 12, 24105 Kiel, Germany
4 Department of Internal Medicine, Hospital of Preetz, Am Krankenhaus 5, 24211 Preetz, Germany
5 Department of Visceral and Transplantation Surgery, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany
6 Division of Gastroenterology, Hepatology and Hepatobiliary Oncology, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany

Correspondence should be addressed to Tom Luedde; tluedde@ukaachen.de

Received 23 March 2019; Revised 27 July 2019; Accepted 7 September 2019; Published 23 October 2019

Academic Editor: Alvaro González

Copyright © 2019 Christoph Roderburg et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background and Aims. Recent data suggested a potential role of miR-143 as a biomarker for systemic inflammation and infection. However, its role in critical illness and sepsis is only poorly understood. Methods. We determined circulating levels of miR-143 in 218 critically ill patients, of which 135 fulfilled sepsis criteria, and compared them to 76 healthy controls. Results were correlated with clinical records. Results. In the total cohort of critically ill patients from a medical intensive care unit (ICU), miR-143 serum levels tended to be lower compared to healthy control samples, but this difference did not reach statistical significance. In ICU patients, serum levels of miR-143 were independent of disease etiology, including the presence of sepsis, or severity of disease. Importantly, low miR-143 serum levels were associated with an unfavorable short- and long-term prognosis in ICU patients. Our study identified different optimal cut-off values at which low miR-143 serum levels predicted mortality with a high diagnostic accuracy. In line with this, concentrations of circulating miR-143 correlated with markers of organ failure such as creatinine, bilirubin, or lactate in our cohort of critically ill patients. Conclusion. Low miR-143 serum levels are indicative for an unfavorable short- and long-term prognosis in critically ill patients admitted to a medical ICU. Our data suggest a previously unrecognized role for miR-143 measurements as a novel prognostic marker in critically ill patients.

1. Introduction

In the last decades, intensive research activities have been made to identify biomarkers for guiding early therapeutic decisions in critically ill patients during ICU treatment [1]. However, due to a lack in specificity and sensitivity, only very few conventional—protein-based—biomarkers have been integrated into daily clinical routine so far. Since the prognosis of critically ill patients is still unacceptably severe, innovative biomarkers reflecting novel pathophysiological concepts are eagerly awaited to improve the therapy of individual critically ill patients.

MicroRNAs (miRNAs) have been demonstrated to act as regulators of gene expression [2]. miRNAs play a critical role in various physiological and pathophysiological processes including inflammation and bacterial infection [3]. Due to their high stability, miRNAs have been proposed as diagnostic, prognostic, and predictive biomarkers in several human diseases [4]. However, the regulation of miRNAs in the serum of patients with critical illness and sepsis is only poorly
understood [5, 6]. As an example, it was recently shown that elevated serum levels of miR-150 might indicate an unfavorable long-term outcome in critically ill patients during ICU treatment [7]. Interestingly, this miRNA was shown to be involved in the regulation of systemic inflammation and bacterial infection [8]. Similar to miR-150, alterations in miR-143 serum levels were recently suggested as a biomarker in the context of critical illness and sepsis [9]. miR-143 is part of the miR-143/miR-145 cluster representing a microRNA cluster involved in the regulation of smooth muscle cell differentiation, leading to a phenotypic switch in response to vascular injury and remodeling [10]. Moreover, alterations in miR-143 expression were found in patients with inflammatory diseases such as inflammatory bowel diseases [11] or cancer [4, 12, 13]. In patients with sepsis, it was shown that, along with other miRNAs, miR-143 was upregulated in the T-cell subpopulation [14]. Based on these observations, we analyzed the diagnostic and prognostic value of miR-143 serum levels in a large cohort of critically ill patients with or without the presence of septic disease who were treated at our medical ICU, as recently described [15].

2. Materials and Methods

2.1. miRNA Isolation from Serum. 400 μl serum was spiked with miScript miRNA mimic SV40 (Qiagen; 2 μM, 1 μl/100 μl serum) for sample normalization. 800 μl phenol (QIAzol) and 200 μl chloroform were added to the sample and mixed vigorously for 15 sec followed by an incubation at room temperature for 10 min. Samples were centrifuged for 15 min at 12,000 g until complete phase separation. The aqueous phase, containing total RNA, was precipitated with 500 μl 100% isopropanol and 2 μl glycogen (Fermentas, St. Leon-Rot, Germany) overnight at -20°C. After centrifugation at 4°C for 30 min (12,000 g), the pellets were washed once with 70% ethanol. Precipitated RNA was resuspended in 30 μl RNase-free water (Ambion, Austin, TX). To assess the quality of RNA, the samples were measured with a NanoDrop spectrophotometer (NanoDrop), and a small RNA assay for Agilent’s Bioanalyzer was performed (Agilent Technologies, Böblingen, Germany).

2.2. Quantitative Real-Time PCR. Quantitative real-time polymerase chain reaction (PCR) was performed as recently described [2, 15]. In detail, 5 μl of extracted total RNA was used to synthesize complementary deoxyribonucleic acid (cDNA) utilizing a miScript Reverse Transcriptase Kit (Qiagen) according to the manufacturer’s protocol and was diluted in suitable amounts of H2O. The rest of the protocol was conducted via the miScript Reverse Transcription Kit according to the manufacturer’s protocol (Qiagen). cDNA samples (2 μl) were used for quantitative real-time PCR in a total volume of 25 μl using the miScript SYBR Green PCR Kit (Qiagen) and miRNA specific primers (Qiagen, primer sequences available online) on a qPCR machine (Applied Biosystems 7300 Sequence Detection System, Applied Biosystems, Foster City, CA). All results are expressed as 2-ΔΔCT and represent the x-fold increase of gene expression compared to the control group. Data were generated and analyzed using the SDS 2.3 and RQ manager 1.2 software packages.

2.3. Sampling and Outcome Definitions in Critically Ill Patients. To obtain serum miR-143 levels at the time point of admission to the ICU (before any therapeutic intervention), blood was collected using serum monovettes (Sarstedt, Germany), centrifuged for 8 minutes at 2000 g using a Rotixa 50 centrifuge (Hettich, Germany) following standard protocols within the Labordiagnostisches Zentrum (LDZ) of the university clinic (RWTH) Aachen for patient routine care. No further clearance was performed before RNA isolation. After centrifugation, samples were immediately placed on ice and frozen at -80°C until RNA isolation. Interleukin-6 (IL-6), Interleukin-10 (IL-10), TNF, soluble urokinase plasminogen activator receptor (suPAR), Osteopontin, Glucocorticoid-induced TNF receptor ligand (GITRL), and A proliferation-inducing ligand (APRIL) were measured as described previously (e.g., [16–20]). All other laboratory markers mentioned within this manuscript were measured as part of clinical routine at the Labordiagnostisches Zentrum (LDZ) of the University Hospital (RWTH) Aachen. Glomerular filtration rates (GFR) were calculated on basis of serum cystatin C levels. ICU mortality was defined as death on ICU; overall mortality included death at the ICU or during the observation period (after discharge from the ICU and hospital).

2.4. Study Design and Patient Characteristics. In the present study, we enrolled 207 patients that were consecutively admitted to the General Internal Medicine intensive care unit (ICU) at the University Hospital Aachen (Table 1). The clinical course of patients was observed in a follow-up period of three years by directly contacting the patients, the patients’ relatives, or their primary care physician. Patients who met the criteria proposed by the American College of Chest Physicians and the Society of Critical Care Medicine Consensus Conference Committee for severe sepsis and septic shock were categorized as sepsis patients, the others as nonsepsis patients [16, 21, 22]. As a control population, we analyzed 76 healthy blood donors (47 males, 29 females, median age 33 years, range 18-67) with normal values for blood counts, C-reactive protein, and liver enzymes.

Patients were included into the study upon providing a written informed consent, and the ethics committees approved this consent procedure. The study protocol was approved by the local ethics committee and conducted in accordance with the ethical standards laid down in the Declaration of Helsinki (ethics committee of the University Hospital Aachen, RWTH University, Aachen, Germany, reference number EK 150/06).

2.5. Statistical Analysis. Data are displayed as median and range considering the skewed distribution of most parameters. Differences between two groups were assessed by the Mann-Whitney U test, and multiple comparisons between more than two groups have been conducted by the Kruskal-Wallis-ANOVA and Mann-Whitney U test for post hoc analysis. Box-plot graphics illustrate comparisons between
subgroups and display a statistical summary of the median, quartiles, range, and extreme values. The whiskers extend from the minimum to the maximum value excluding outside and far out values which are displayed as separate points. An outside value (indicated by an open circle) was defined as a value that is smaller than the lower quartile minus 1.5-times the interquartile range or larger than the upper quartile plus 1.5-times the interquartile range. A far out value was defined as a value that is smaller than the lower quartile minus three times the interquartile range or larger than the upper quartile plus three times the interquartile range. All values, including "outliers," have been included for statistical analyses. Correlations between variables have been analyzed using the Spearman correlation test, and values of $p < 0.05$ were considered statistically significant. The Kaplan-Meier curves were plotted to display the impact on survival. The receiver operating characteristic (ROC) curve analysis and the derived area under the curve (AUC) statistic provide a global and standardized appreciation of the accuracy of a marker or a composite score for predicting an event. ROC curves were generated by plotting sensitivity against 1 - specificity. All statistical analyses were performed with SPSS version 12.0 (SPSS, Chicago, IL, USA).

### 3. Results

#### 3.1. miR-143 Serum Levels in Critically Ill Patients and Healthy Controls

Based on recent data suggesting a role for miR-143 as a biomarker in the context of critical illness and sepsis [9], we analyzed serum concentrations of miR-143 in 218 critically ill patients and 76 healthy blood donors as a control population. In these analyses, we found a trend towards lower levels of miR-143 in ICU patients compared to control samples (Figure 1(a)). However, due to the large variance in the control group, the difference did not reach statistical significance ($p = 0.07$). Next, we examined whether serum levels of miR-143 reflect disease severity and compared miR-143 serum concentrations between patients with a more severe disease state according to a higher APACHE II score and those with a less severe state of disease (Figure 1(b)). Unexpectedly, no difference in miR-143 serum levels became apparent between both groups. In line with these results, miR-143 levels did not correlate with APACHE II, SAPS2, or SOFA scores in our cohort of critically ill patients (Table 2).

Metabolic comorbidities were shown to influence the outcome of critically ill patients [23]. Since decreased serum levels of miR-143 were recently described in patients with obesity [24], we next analyzed the impact of preexisting type 2 diabetes or obesity in our cohort of critically ill patients, revealing that miR-143 serum concentrations were independent of these comorbidities (Figures 1(c) and 1(d)). In line with this, miR-143 levels did not correlate with routinely used markers of metabolic diseases in our cohort of critically ill patients (Table 2).

#### 3.2. miR-143 Serum Levels Are Unaltered in Patients with Sepsis

Our cohort of critically ill patients consisted of 135 patients who fulfilled sepsis criteria and 72 patients with another disease etiology (Table 3). Recently, elevated serum concentrations of miR-143 were found in Asian patients with sepsis ($n = 103$) compared to patients with SIRS ($n = 95$) or healthy controls ($n = 40$). We therefore analyzed miR-143 serum levels in patients with or without septic disease in our cohort of patients. In our ICU cohort, serum levels of miR-143 did not differ between these groups (Figure 2(a)). In line with these results, correlation analyses demonstrated that miR-143 concentrations did not correlate to routinely used sepsis markers such as C-reactive protein (CRP), procalcitonin (PCT), or tumor necrosis factor (TNF) (Table 2). Furthermore, subgroup analyses did not identify an etiology with a specific regulation of miR-143 (Figure 2(b)).

#### 3.3. miR-143 Serum Levels Predict ICU Survival in Critically Ill Patients

To test whether circulating miR-143 might be useful to predict treatment survival in critically ill patients, we next analyzed serum levels of miR-143 in patients that succumbed to death during ICU treatment and those who survived. Interestingly, patients who survived their ICU stay displayed significantly higher levels compared to those who died (Figure 3(a)). Similarly, Kaplan-Meier curve analyses revealed that patients with low miR-143 levels (below 116.16 AU) showed a significantly impaired survival probability at the ICU (Figure 3(b)). To substantiate these findings, we next applied the approach of Ray et al. [25] to determine an optimal threshold with the highest Youden index for miR-143 levels predicting the patients' survival during ICU treatment. This analysis revealed a relative miR-143 concentration of 116.16 (AU) for the best sensitivity and specificity to decide whether a patient will survive or not. Using this optimal cut-off value, we performed the Kaplan-Meier curve analysis, showing that patients with

### Table 1: Baseline patient characteristics.

| Parameter                  | All patients |
|----------------------------|--------------|
| Number                     | 207          |
| Sex (male/female)          | 135/72       |
| Age median (range) (years) | 63 (18-89)   |
| APACHE II score median (range) | 17 (2-43) |
| SAPS2 score median (range) | 43.0 (0-79)  |
| ICU days median (range)    | 7 (1-83)     |
| Death during ICU (%)       | 22.2%        |
| Death during ICU or follow-up (%) | 42.5% |
| Body mass index (BMI)      | 26.78 (16.6-86.5) |
| Creatinine                 | 1.3 (0-15)   |
| Albumin                    | 27.3 (15.2-52.2) |
| WBC median (range) (×10⁹/µl) | 12.15 (0.1-67.4) |
| CRP median (range) (mg/dl) | 95.5 (<5-230) |
| Procalcitonin median (µg/l) | 0.7 (0-180.6) |
| Interleukin-6 median (range) (pg/ml) | 105 (0-83,000) |
| Tumor necrosis factor median (pg/ml) | 19 (4.9-140) |

APACHE: Acute Physiology and Chronic Health Evaluation; CRP: C-reactive protein; ICU: intensive care unit; SAPS: simplified acute physiology score; WBC: white blood cell count.
high miR-143 serum concentrations above the cut-off value had a more favorable prognosis compared to those with lower values (Figure 3(c)). Finally, we hypothesized that low levels of miR-143 could discriminate between critically ill patients that survive ICU treatment and those that do not. Therefore, we attempted to compare its predictive accuracy with other laboratory parameters routinely accessed in the context of critical illness. The ROC curve analysis revealed higher AUC statistics for miR-143 ($AUC = 0.628$) compared to CRP ($AUC = 0.563$), the leukocyte count ($AUC = 0.491$), creatinine ($AUC = 0.599$), or the INR value (0.604) (Figure 3(d)).

3.4. miR-143 Serum Levels Predict Overall Survival in Critically Ill Patients. Since many of the patients died after initially being successfully discharged from the ICU, we subsequently analyzed miR-143 serum levels in patients that died during long-term follow-up and patients who survived. Of note, this analysis revealed that survivors demonstrated significantly higher miR-143 levels than patients who died during long-term follow-up (Figure 4(a)). Consequently, the Kaplan-Meier curve analysis revealed that patients with lower levels of circulating miR-143 displayed an impaired long-term prognosis compared to patients with higher miR-143 levels (Figure 4(b)). We again applied the Youden index to determine the optimal threshold of circulating miR-143 to predict overall survival in our cohort of critically ill patients, revealing that a miR-143 value of 45.41 (AU) allows best to distinguish between patients that survived and those that died during the long-term follow-up (Figure 4(c)). Similar to our previous analyses, low miR-143 concentrations were associated with an impaired prognosis. We finally performed the ROC curve analysis to compare the predictive value of circulating miR-143 regarding the patients’ overall survival with other routine laboratory parameters or prognostic scores routinely accessed in the context of critical illness. The ROC curve analysis revealed higher AUC statistics for miR-143 ($AUC = 0.574$) compared to CRP ($AUC = 0.568$), the leukocyte count ($AUC = 0.472$), creatinine ($AUC = 0.548$), or the INR value (0.525) (Figure 4(d)).

---

**Figure 1:** Serum miR-143 levels of critically ill patients at ICU admission. (a) qPCR was used to determine concentrations of circulating miR-143 at admission to the ICU. This analysis revealed a trend toward lower miR-143 concentrations in critically ill patients ($n = 218$) as compared with healthy controls ($n = 76$). (b) Serum miR-143 concentrations were independent of the disease severity. (c) Serum concentrations of miR-143 were similar in patients with or without diabetes mellitus type 2. (d) Serum concentrations of miR-143 were similar in patients with or without obesity.
3.5. miR-143 Serum Levels Are Associated with Markers of Organ Dysfunction in Critically Ill Patients. To identify mechanisms involved in the regulation of miR-143 in critically ill patients, we performed correlation analyses between miR-143 and a broad panel of laboratory markers assessed in clinical routine. While concentrations of miR-143 did not correlate with markers of inflammation or bacterial infection (Table 2), we found a strong correlation between miR-143 and indicators of organ failure in critical illness. In detail, serum levels of miR-143 correlated with a decreased renal function assessed by the glomerular filtration rate (GFR) of cystatin C ($r = 0.289$, $p = 0.001$), elevated creatinine ($r = -0.254$, $p < 0.001$), and urea serum concentrations ($r = -0.294$, $p < 0.001$). In addition to renal dysfunction, miR-143 concentrations significantly correlated with markers of liver injury such as aspartate aminotransferase (AST; $r = 0.159$, $p = 0.026$), alanine aminotransferase (ALT; $r = 0.206$, $p = 0.003$), glutamate dehydrogenase (GLDH; $r = 0.150$, $p = 0.039$), and bilirubin ($r = 0.185$, $p = 0.035$) (Supplementary Figure 1). Moreover, miR-143 concentrations correlated with elevated lipase and amylase serum concentrations as indicators for the presence of acute pancreatitis. In line with this association between miR-143 and organ failure, circulating miR-143 also correlated with serum levels of lactate ($r = -0.173$, $p = 0.014$), cardiac dysfunction (BNP; $r = -0.383$, $p < 0.001$), and the patients’ survival time ($r = -0.348$, $p = 0.006$).

4. Discussion

Despite continuous advances in diagnostic modalities, triage, and therapeutic management, critically ill patients still represent a major clinical challenge. In this context, besides specific triage systems, various laboratory markers potentially allowing decisions about patients’ treatment and clinical course were proposed. As such, next to routinely used markers (e.g., CRP or PCT; [26]), a variety of different experimental protein-based markers such as A proliferation-inducing ligand (APRIL), suPAR, and Osteopontin [17, 27–29] were tested. However, the lack of prognostic sensitivity or specificity for such protein-based markers as well as marker-specific confounding parameters (like sepsis) hampers the translation into routine clinical algorithms that could be applied to heterogeneous patient populations [26, 30]. Compared to “conventional” protein-based markers, circulating miRNAs harbour several advantages: circulating miRNAs are extraordinarily stable towards conditions that usually would degrade most proteins in serum or blood [31]. Moreover, miRNAs are much less complex than most other biological biomarkers [32]. Therefore, many authors hypothesized that circulating miRNAs might perform better in the detection of sepsis or prognosis prediction in critically ill patients. As an example, miR-150 levels were found to be downregulated in patients with urosepsis [33] and predictive for an impaired patients’ survival in a cohort of critically ill patients comprising various disease etiologies and severities [15]. In the present study, we demonstrate that miR-143 serum levels appear rather reduced in patients with critical illness when
compared to healthy controls and unchanged between patients with septic disease etiology and patients with SIRS. Our results are partially in contrast to previously published results demonstrating elevated levels of miR-143 in patients with sepsis [9]. On the one hand, this might be related to differences in the patient cohorts (unselected critically ill medical patients in our work) or the time point of sampling; on the other hand, technical aspects (method of sample collection, data normalization, and analysis) might also account for diverging findings. In this respect, it is important to note that in the context of critical illness and sepsis, the interstudy variances in terms of miRNA regulation patterns are enormous and the fact that different studies show even opposing results with respect to the deregulation of miRNA levels is not uncommon [7, 34, 35]. In an attempt to avoid these biases, we had implemented strict protocols for sample collection and handling in the present study sample. Moreover, in our study, analyses were normalized using spiked-in RNA, which is regarded as the “gold standard” by most authors [36–38]. Finally, the cut-offs for Kaplan-Meier curve analysis were defined using the broadly accepted Youden index, potentially providing different cut-offs compared to previously published studies [15, 35, 39, 40]. These principles might help to overcome technical challenges of miRNA analysis from serum or plasma, giving rise to the expectation that circulating miRNAs might become novel, highly attractive biomarkers in the context of critical illness. Nevertheless, many technical aspects in the context of RNA isolation from serum remain unsolved. As an example, hemolysis may occur during sample handling and bias results. In our analysis, miR-143 concentrations did neither correlate with sodium nor with LDH serum concentrations and only very weakly with bilirubin serum levels, representing markers for hemolysis.

Alterations in miR-143 expression have recently been described in the context of carcinogenesis and cancer progression [41]. Several studies have analyzed the role of circulating miR-143 as a biomarker in malignant diseases. Just recently, it was demonstrated that patients with acute myeloid leukemia and esophageal adenocarcinoma, disease states which are associated with the activation of immune cells, display decreased serum levels of miR-143 [42, 43], which is in line with our results. Moreover, miR-143 might be directly involved in systemic inflammation and defending bacterial infection. As examples, it was demonstrated that miR-143 inhibits Propionibacterium acnes-mediated inflammatory response in the skin and that miR-143 is downregulated in chronic ulcerative colitis, where it might contribute to inflammation colitis-associated carcinogenesis [11]. Most importantly, miR-143 was upregulated in leukocytes after LPS injection in humans [44]. Interestingly, these observations were not in line with a similar regulation of circulating miR-143 in our large collective of ICU patients, since miR-143 showed only a nonsignificant trend towards lower levels in critically ill patients compared to controls. However, we detected lower levels of miR-143 in patients who succumbed to death during ICU treatment, when compared to patients that survived. More importantly, in our analysis, lower levels of miR-143 were significantly associated with an unfavorable short- and long-term prognosis and miR-143 predicted patients’ outcome with a higher accuracy than classical markers of organ failure such as creatinine or INR. It was recently suggested that miR-143 is involved in metabolic processes such as insulin tolerance and type II diabetes mellitus. Moreover, it was shown that aerobic exercise can prevent type II diabetes mellitus by downregulating miR-143. However, at least in our cohort of critically ill patients, no direct correlation between diabetes and miR-143 serum levels was found. Notably, since we have not systematically assessed complications of diabetes in our database, we cannot exclude that there might be an association between miR-143 levels and diabetes complications.

Figure 2: Serum miR-143 concentrations are unaltered in sepsis. (a) miR-143 serum levels were analyzed by qPCR in critically ill patients with sepsis and patients without septic etiology of critical illness. (b) miR-143 serum did not vary between the different etiologies of septic or nonseptic disease.
Our study bears several limitations and potential bias such as interpretation/selection bias [45] and the lack of pathophysiological mechanisms explaining the regulation of miR-143 in critical illness/sepsis. However, we clearly demonstrate that circulating miR-143 might be indicative for patient prognosis. miR-143 levels upon admission were closely associated with ICU and long-term mortality. Reduced miR-143 concentration indicated an unfavorable prognosis. Furthermore, it is important to note that changes in miR-143 serum concentrations have been described in numerous pathological conditions (see above). Therefore, the use of a specific marker for the diagnosis of sepsis seems to be unattractive at present. Nevertheless, our data suggest that measurements of miR-143 might represent a novel tool to estimate prognosis of critically ill patients and should give rise to further research in order to validate our results in larger and prospective studies on critically ill patients.

5. Conclusions

(i) miR-143 serum concentrations were not altered in samples from critically ill patients taken at admission to the ICU when compared to those from healthy blood donors as controls

(ii) Low miR-143 serum concentrations were lower in critically ill patients that succumbed to death
compared to survivors and predicted an unfavorable outcome with higher accuracy.

**Data Availability**

The data used to support the findings of this study are restricted by the ethics committee of the university clinic (RWTH) Aachen to protect patient privacy. Data are available upon meaningful request from med3@ukaachen.de for researchers who meet the criteria for access to confidential data.

**Ethical Approval**

The institutional ethics committees approved this consent procedure. The study protocol was conducted in accordance with the ethical standards laid down in the Declaration of Helsinki (ethics committee of the University Hospital Aachen, RWTH University, Aachen, Germany, reference number EK 150/06).

**Consent**

Patients were included into the study upon providing a written informed consent.

**Conflicts of Interest**

The authors declare that in the past five years they have not received reimbursements, fees, funding, or salary from an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in
the future, and that no such an organization is financing this
manuscript. They do not hold any stocks or shares in an
organization that may in any way gain or lose financially
from the publication of this manuscript, either now or in
the future. They do not hold or are not currently applying
for any patents relating to the content of the manuscript.
They have not received reimbursements, fees, funding, or sal-
ary from an organization that holds or has applied for patents
relating to the content of the manuscript. They do not have
any other financial competing interests.

Authors’ Contributions
CR, FT, ML, FB, MS, SR, CT, AK, and TL designed the study,
analyzed the data, and wrote the manuscript. SR, MV, and
DVC performed the measurements. CR, SR, and FT per-
formed the statistical analyses. AK and FT collected data
and organized patient recruitment. Christoph Roderburg
and Alexander Koch contributed equally to this work. Frank
Tacke and Tom Luedde jointly supervised this manuscript.

Acknowledgments
This work was supported by a Mildred-Scheel Endowed
Professorship from the German Cancer Aid (Deutsche Krebshilfe), the German Research Foundation (DFG) (LU
1360/3-1 and SFB-TRR57/P06), the Interdisciplinary Centre
for Clinical Research (IZKF) Aachen Germany, and the Ernst
Jung Foundation Hamburg to TL; a project grant from the
German Research Foundation (DFG RO 4317/4-1) to CR;
a START grant from the medical faculty RWTH Aachen
University to CR and SR; and a project grant of the German
Center for Cardiovascular Diseases (DZHK, B18-005Ext) to
Tacke and Tom Luedde jointly supervised this manuscript.

Supplementary Materials
Correlation analysis of miR-143 serum levels and different
laboratory parameters. (Supplementary Materials)

References
[1] P. Schuetz, V. Chiappa, M. Briel, and J. L. Greenwald, “Proca-
citonin algorithms for antibiotic therapy decisions: a systematic
review of randomized controlled trials and recommendations
for clinical algorithms,” Archives of Internal Medicine,
vol. 171, pp. 1322–1331, 2011.
[2] C. Roderburg, G. W. Urban, K. Bettermann et al., “Micro-RNA
profiling reveals a role for miR-29 in human and murine liver
fibrosis,” Hepatology, vol. 53, no. 1, pp. 209–218, 2011.
[3] F. Schueller, S. Roy, M. Vucur, C. Trautwein, T. Luedde, and
C. Roderburg, “The role of miRNAs in the pathophysiology of
liver diseases and toxicity,” International Journal of Molecu-
lar Sciences, vol. 19, no. 1, p. 261, 2018.
[4] Z. Kanaan, S. N. Rai, M. R. Eichenberger et al., “Differential
microRNA expression tracks neoplastic progression in inflam-
matory bowel disease-associated colorectal cancer,” Human
Mutation, vol. 33, pp. 551–560, 2012.
[5] C. N. Correia, N. C. Nalpas, K. E. McLoughlin et al., “Circulat-
ing microRNAs as potential biomarkers of infectious disease,”
Frontiers in Immunology, vol. 8, p. 118, 2017.
[6] F. Benz, S. Roy, C. Trautwein, C. Roderburg, and T. Luedde,
“Circulating microRNAs as biomarkers for sepsis,” Interna-
tional Journal of Molecular Sciences, vol. 17, no. 1, p. 78, 2016.
[7] J. F. Wang, M. L. Yu, G. Yu et al., “Serum miR-146a and
miR-223 as potential new biomarkers for sepsis,” Biochemical
and Biophysical Research Communications, vol. 394, no. 1,
pp. 184–188, 2010.
[8] E. Sonkoly, M. Stahle, and A. Pivarcsi, “MicroRNAs and
immunity: novel players in the regulation of normal immune
function and inflammation,” Seminars in Cancer Biology,
vol. 18, no. 2, pp. 131–140, 2008.
[9] Y. Han, Q. C. Dai, H. L. Shen, and X. W. Zhang, “Diagnostic
value of elevated serum miRNA-143 levels in sepsis,” Journal
of International Medical Research, vol. 44, no. 4, pp. 875–
881, 2016.
[10] F. Vacante, L. Denby, J. C. Sluimer, and A. H. Baker, “The
function of miR-143, miR-145 and the MiR-143 host gene in
cardiovascular development and disease,” Vascular Pharma-
cotherapy, vol. 112, pp. 24–30, 2019.
[11] J. R. Pekow, U. Dougherty, R. Mustafi et al., “miR-143 and
miR-145 are downregulated in ulcerative colitis: putative regu-
lators of inflammation and protooncogenes,” Inflammatory
Bowel Diseases, vol. 18, pp. 94–100, 2012.
[12] H. Zhu, U. Dougherty, V. Robinson et al., “EGFR signals
downregulate tumor suppressor miR-143 and miR-145 in
Western diet-promoted murine colon cancer: role of G1 regu-
lators,” Molecular Cancer Research, vol. 9, pp. 960–975, 2011.
[13] L. Chang, D. Zhang, H. Shi, Y. Bian, and R. Guo, “MiR-143
inhibits endometrial cancer cell proliferation and metastasis
by targeting MAPK1,” Oncotarget, vol. 8, no. 48, pp. 84384–
84395, 2017.
[14] P. Mohnle, S. Hirschberger, L. C. Hinske et al., “Micro-
RNAs 143 and 150 in whole blood enable detection of T-cell
immunoparalysis in sepsis,” Molecular Medicine, vol. 24,
p. 54, 2018.
[15] C. Roderburg, M. Luedde, D. Vargas Cardenas et al., “Circulating
microRNA-150 serum levels predict survival in patients
with critical illness and sepsis,” PLoS One, vol. 8, no. 1, article
e54612, 2013.
[16] A. Koch, S. Voigt, C. Kruschinski et al., “Circulating soluble
urokinase plasminogen activator receptor is stably elevated
during the first week of treatment in the intensive care unit
and predicts mortality in critically ill patients,” Critical Care,
vol. 15, article R63, 2011.
[17] C. Roderburg, F. Benz, D. V. Cardenas et al., “Persistently ele-
vated osteopontin serum levels predict survival in patients
with critical illness and sepsis,” Critical Care, vol. 19, no. 1,
p. 271, 2015.
[18] C. Roderburg, F. Benz, F. Schüller et al., “Serum levels of TNF
receptor ligands are dysregulated in sepsis and predict mortal-
ity in critically ill patients,” PLoS One, vol. 11, article e0153765,
2016.
[19] C. Roderburg, A. Koch, F. Tacke et al., “Serum concentrations of
A Proliferation-Inducing Ligand (APRIL) are elevated in
sepsis and predict mortality in critically ill patients,” Journal
of Critical Care, vol. 28, pp. 882.e1–882.e11, 2013.
[20] M. Luedde, M. E. Spehmann, H. J. Hippe et al., “Serum levels
of kisspeptin are elevated in critically ill patients,” PLoS One,
vol. 13, article e0206064, 2018.
[21] O. A. Gressner, A. Koch, E. Sanson, C. Trautwein, and F. Tacke, “High C5a levels are associated with increased mortality in sepsis patients — no enhancing effect by actin-free Gc-globulin,” *Clinical Biochemistry*, vol. 41, pp. 974–980, 2008.

[22] Y. Kochi, Y. Okada, A. Suzuki et al., “A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility,” *Nature Genetics*, vol. 42, no. 6, pp. 515–519, 2010.

[23] A. Koch, E. Sanson, S. Voigt, A. Helm, C. Trautwein, and F. Tacke, "Serum adiponectin upon admission to the intensive care unit may predict mortality in critically ill patients," *Journal of Critical Care*, vol. 26, pp. 166–174, 2011.

[24] I. D. Kilic, Y. Dodurga, B. Uludag et al., "MicroRNA -143 and -223 in obesity," *Gene*, vol. 560, no. 2, pp. 140–142, 2015.

[25] P. Ray, Y. Le Manach, B. Riou, and T. T. Houle, "Statistical evaluation of a biomarker," *Anesthesiology*, vol. 112, no. 4, pp. 1023–1040, 2010.

[26] C. Pierrakos and J.-L. Vincent, “Sepsis biomarkers: a review,” *Critical Care*, vol. 14, article R15, 2010.

[27] A. Koch, R. Weiskirchen, H. W. Zimmermann, E. Sanson, C. Trautwein, and F. Tacke, “Relevance of serum leptin and leptin-receptor concentrations in critically ill patients,” *Meditors of Inflammation*, vol. 2010, Article ID 473540, 7 pages, 2010.

[28] A. Koch, E. Sanson, A. Helm, S. Voigt, C. Trautwein, and F. Tacke, “Regulation and prognostic relevance of serum ghrelin concentrations in critical illness and sepsis,” *Critical Care*, vol. 14, no. 3, article R94, 2010.

[29] A. Koch, O. A. Gressner, E. Sanson, F. Tacke, and C. Trautwein, “Serum resistin levels in critically ill patients are associated with inflammation, organ dysfunction and metabolism and may predict survival of non-septic patients,” *Critical Care*, vol. 13, no. 3, article R95, 2009.

[30] A. Koch and F. Tacke, “Risk stratification and triage in the emergency department: has this become ‘suPAR’ easy?,” *Journal of Internal Medicine*, vol. 272, no. 3, pp. 243–246, 2012.

[31] H. Schwarzenbach, N. Nishida, G. A. Calin, and K. Pantel, “Clinical relevance of circulating cell-free microRNAs in cancer,” *Nature Reviews Clinical Oncology*, vol. 11, no. 3, pp. 145–156, 2014.

[32] K. Wang, S. Zhang, B. Marzolf et al., “Circulating microRNAs, potential biomarkers for drug-induced liver injury,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 106, pp. 4402–4407, 2009.

[33] C. Vasilescu, S. Rossi, M. Shimizu et al., “MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis,” *PLoS One*, vol. 4, no. 10, article e7405, 2009.

[34] H. J. Wang, P. J. Zhang, W. J. Chen, D. Feng, Y. H. Jia, and L. X. Xie, “Four serum microRNAs identified as diagnostic biomarkers of sepsis,” *Journal of Trauma and Acute Care Surgery*, vol. 73, no. 4, pp. 850–854, 2012.

[35] F. Benz, F. Tacke, M. Luedde et al., “Circulating microRNA-223 serum levels do not predict sepsis or survival in patients with critical illness,” *Disease Markers*, vol. 2015, Article ID 384208, 10 pages, 2015.

[36] P. S. Mitchell, R. K. Parkin, E. M. Kroh et al., “Circulating microRNAs as stable blood-based markers for cancer detection,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, pp. 10513–10518, 2008.